Rapport Therapeutics, Inc. (RAPP) Stock
3 of the hedge funds AlphaScala tracks reported RAPP in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $8.95M. Company insiders reported 1 open-market buy and 21 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own RAPP?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 215K | $8.95M | +22% |
| Millennium Management Israel Englander | 155K | $6.46M | -52% |
| Citadel Ken Griffin | 82K | $3.44M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Rapport Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 21, 26 | Ignelzi Troy A. | Chief Financial Officer | BUY | 5.5K | $144K |
| Oct 7, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 1.1K | $35K |
| Oct 6, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 3.4K | $108K |
| Sep 30, 26 | Gault Cheryl | Chief Operating Officer | SELL | 7.9K | $262K |
| Sep 30, 26 | Gault Cheryl | Chief Operating Officer | SELL | 2.1K | $70K |
| Sep 23, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 2.0K | $76K |
| Sep 23, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 215 | $9K |
| Sep 23, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 43 | $2K |
| Sep 8, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 7.1K | $325K |
| Sep 8, 26 | Ceesay Abraham | Chief Executive Officer | SELL | 1.1K | $49K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →RAPP price chart
Powered by TradingViewWhat does Rapport Therapeutics, Inc. do?
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines that target specific neurocircuits in the brain through receptor-associated proteins (RAPs). The company addresses a fundamental challenge in neuromedicine by creating small molecule therapeutics that can selectively modulate disease-driving neural circuits, overcoming the indiscriminate effects of conventional neurological treatments that often result in limited efficacy and significant side effects. Rapport's pipeline targets central nervous system disorders including focal epilepsy, pain, bipolar disorder, and hearing disorders. The company's lead program, RAP-219, represents a novel approach to neuroanatomical specificity by selectively targeting TARPγ8, a receptor protein associated with clinically validated epilepsy targets. Founded in 2022 through a collaboration between Third Rock Ventures and Johnson & Johnson Innovation, Rapport operates from offices in Boston, Massachusetts and San Diego, California, positioning itself at the forefront of precision neuromedicine innovation.